LIMN Stock Summary and Trading Ideas (Liminatus Pharma - Class A | NASDAQ:LIMN)

Liminatus Pharma Inc is a clinical-stage biopharmaceutical company engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C. The company is developing a next generation CD47 immune checkpoint inhibitor that enables cancer cells to evade detection by the immune system. Anti-CD47 monoclonal antibodies generally induce anemia and thrombocytopenia due to their binding to red blood cells and platelets. The Liminatus CD47 mAb has shown to preferentially bind to immune cells, but not to red blood cells and platelets and does not induce hemolysis. The clinical candidate is currently in the late preclinical stage.

Liminatus Pharma - Class A trades on the NASDAQ stock market under the symbol LIMN.

As of May 13, 2026, LIMN stock price was flat at $0.19 with 294,302 million shares trading.

LIMN has a beta of 4.45, meaning it tends to be more sensitive to market movements. LIMN has a correlation of 0.04 to the broad based SPY ETF.

LIMN has a market cap of $7.47 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that LIMN belongs to (by Net Assets): VXF.

LIMN has underperformed the market in the last year with a price return of -97.3% while the SPY ETF gained +28.5%. LIMN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -60.8% and -6.8%, respectively, while the SPY returned +9.1% and +4.2%, respectively.

LIMN support price is $.18 and resistance is $.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LIMN shares will trade within this expected range on the day.